Think Bioscience raised $55 million in a Series A led by Regeneron Ventures and other prominent investors to advance small‑molecule programs against targets considered historically ‘undruggable.’ The Boulder, Colorado‑based company uses synthetic biology approaches to reveal hidden binding footholds and develop novel chemotypes. The financing will fund lead programs, including an effort directed at Noonan syndrome, a rare genetic disorder with no approved disease‑modifying treatments. Management highlighted the platform’s capacity to identify unconventional binding sites and accelerate medicinal chemistry around those pockets. Investors framed the round as a bet on platform‑driven discovery that can unlock high‑need, genetically defined diseases. Source: company release and investor statements cited in the coverage.